Targeted Protein Degradation Market Size, Share & Industry Analysis, By Type (Proteolysis-Targeting Chimeras (PROTACs), Molecular Glues, Selective Estrogen Receptor Degraders (SERD), Lysosome-Targeting Chimeras (LYTACs), and Others), By Formulation (Oral and Parenteral), By Application (Therapeutics {Oncology, Neurodegenerative Disorders, and Others} and Research), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others), and Regional Forecast, 2026-2034

Region : Global | Report ID: FBI115618 | Status : Ongoing

KEY MARKET INSIGHTS

The global targeted protein degradation market size was valued at USD 560.0 million and is projected to reach USD 2,410.0 million by 2032, exhibiting a CAGR of 20.0% during the forecast period.

The market is poised for strong growth primarily driven by the rising number of research and development initiatives along with clinical trials based on this workflow. The efficiency of protein degraders in late-stage trials have led to increasing significance in the potential of these therapeutic modalities. Many key companies are participating in strategic collaborations to advance their research programs.

For instance, in October 2025, Kazia Therapeutics collaborated with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader in the development of cancer immunotherapy.

Moreover, strategic activities such as research and development partnerships, increasing clinical trials, and collaborations among key operational entities are anticipated to drive the growth of the market in the upcoming years.

Targeted Protein Degradation Market Driver

Effectiveness of Targeted Protein Degradation in Therapeutic Applications to Drive Market Growth

One of the major factors driving the market growth is the ability of these targeted protein degraders to target previously un-druggable proteins. Many proteins that lacked active sites for conventional binding were not addressed previously by small molecules. Targeted protein degraders overcome this limitation by eliminating proteins altogether rather than blocking their activity. This innovative approach has opened new therapeutic possibilities and urged many companies for active investment for the development of this technology.

For instance, in May 2025, GlycoEra secured USD 130.0 million to progress IgG4-targeted protein degrader for autoimmune diseases. Such developments are anticipated to drive the market growth.

Download Free sample to learn more about this report.

According to data published by National Breast Cancer Foundation, Inc. in September 2025, an estimated 316,950 new cases of breast cancer in women and 2,800 men will be diagnosed with invasive breast cancer, and an additional 59,080 new cases of non-invasive (in situ) breast cancer will be diagnosed.

Targeted Protein Degradation Market Restraint

Risk Associated with Off-Target Protein Degradation to Hamper Adoption of Novel Therapies

One of the major market challenges in the targeted protein degradation market is the risk of off-target protein degradation posing potential safety and toxicity concerns. This is due to the unintended removal of essential proteins, which may lead to adverse effects.

For instance, in November 2024, Frontiers in Molecular Biosciences published an article titled ‘Precision-engineered PROTACs minimize off-tissue effects in cancer therapy’ which reported that neutropenia was observed as a side effect during the clinical trial of CFT7455 and highlighted such effects as examples of off-tissue toxicity risks in PROTAC development.

Targeted Protein Degradation Market Opportunity

Expansion of Disease Indications to Offer Lucrative Growth Opportunities

The expansion of disease indications represents a major growth opportunity for the targeted protein degradation market. While cancer currently accounts for the majority of clinical TPD programs, increasing research initiatives have unlocked applications in neurodegenerative, autoimmune, inflammatory, infectious, and metabolic diseases. This shift dramatically widens the addressable market potential providing lucrative growth opportunity.

For instance, in March 2025, AnHorn Medicines, launched AH-001, a first-in-class protein degrader for androgenetic alopecia (AGA), in Phase I clinical trial in the U.S. This innovative approach has the potential to offer a more effective and long-lasting solution for millions of individuals suffering from AGA worldwide. Such factors are poised to offer new growth avenues to the global market.

Segmentation

By Type

By Formulation

By Application

By End User

By Region

· Proteolysis-Targeting Chimeras (PROTACs)

· Molecular Glues

· Selective Estrogen Receptor Degraders (SERD)

· Lysosome-Targeting Chimeras (LYTACs)

· Others

· Oral

· Parenteral

· Therapeutics

Oncology
Neurodegenerative Disorders
Others

· Research

· Pharmaceutical and Biotechnology Companies

· Academic and Research Institutes

· Others

· North America (U.S. and Canada)

· Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and the Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)

· Latin America (Brazil, Mexico, and the Rest of Latin America)

· Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Key Insights

The report covers the following key insights:

Overview: Expanding Applications of Targeted Protein Degradation
Technological Advancements in the Targeted Protein Degradation
New Product Launches, By Key Players
Key Industry Developments (Mergers, Acquisitions and Partnerships)
Pipeline Analysis, By Key Companies

Analysis by Type

On the basis of type, the global targeted protein degradation market is segmented into proteolysis-targeting chimeras (PROTACs), molecular glues, Selective Estrogen Receptor Degraders (SERD), Lysosome-Targeting Chimeras (LYTACs), and others.

Among these, the PROTACs segment is expected to hold a significant market share. The high segmental share is due to its advanced clinical maturity, broad applicability, and increasing clinical trials. This is one of the most promising type of targeted protein degradation.

For Instance, in February 2024, Arvinas, Inc. dosed its first subject in its Phase 1 clinical trial of ARV-102, the Company’s first oral PROTAC (PROteolysis-TArgeting Chimera) protein degrader in development to treat neurodegenerative diseases.

Analysis by Formulation

On the basis of formulation, the market is classified into oral and parenteral.

Among these, the oral formulation segment dominates the targeted protein degradation market, primarily due to the small-molecule nature of most PROTACs and molecular glues. These factors enable convenient and non-invasive administration. Underscoring these advantages, many key companies are collaborating to develop oral targeted protein degraders.

For instance, in July 2021, Arvinas, Inc. collaborated with Pfizer Inc. to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is one of the leading causes of breast cancers.

Analysis by Application

The market is subdivided into therapeutics {oncology, neurodegenerative disorders and others} and research based on application.

The therapeutics segment is anticipated to account for major revenue share over the forecasted period. The dominance of the segment is due to the widespread application of these targeted protein degradation drugs in treating complex diseases such as cancer, autoimmune, and neurodegenerative disorders. The segment is anticipated to grow with the increasing prevalence of these diseases and many advancing therapeutic pipelines.

For example, in 2022, GLOBOCAN reported that 5 year prevalent cases for cancer were 53,504,187 across the globe, among which 2,296,840 were of breast cancer.

Analysis by End User

In terms of end user, the market is divided into pharmaceutical and biotechnology companies, academic and research institutes, and others.

The pharmaceutical and biotechnology companies segment dominates the targeted protein degradation market. These companies account for the majority of R&D investments, strategic collaborations, and intellectual property related to degrader technologies driving innovation. Consequently, pharmaceutical and biotech firms dominate due to their funding capability and product development focus.

Regional Analysis

Request for Customization to gain extensive market insights.

The market, on the basis of region, has been studied across North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa.

North America accounted for around 45% share of the global targeted protein degradation market in 2024. The dominance of the region is due to the strong biotechnology ecosystem, high R&D investment, and presence of leading companies. Additionally, the early adoption of advanced drug discovery technologies positions North America as the global hub for targeted protein degradation research and commercialization. Further, strategic collaborations among key companies in the region drive the dominance.

For instance, in July 2023, Astellas Pharma Inc. collaborated with Cullgen Inc. to discover multiple innovative protein degraders.

Europe is expected to grow with a significant CAGR during the forecast period due to expanding biopharmaceutical research base, government-backed funding programs, and active participation of leading academic institutions in degrader discovery. Furthermore, underscoring the rising demand, many key companies are focusing on the expansion of manufacturing capabilities to meet the rising demand.

For instance, in July 2024, Draupnir Bio secured USD 13.0 million seed funding to advance their development of an oral, small molecule degraders of extracellular proteins.

Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The growth in the region is attributed to increasing biotechnology investments, expanding clinical trial infrastructure, and the rise of domestic innovators. Moreover, partnerships between Asian biotech firms and Western pharmaceutical companies are accelerating technology transfer and local pipeline growth.

For instance, in July 2023, Astellas Pharma Inc. collaborated with PeptiDream Inc to discover novel protein degraders for two targets selected by Astellas. Under the agreement, the company will have the option to select up to three additional targets to be included in the collaboration. Such developments are anticipated to drive growth in the region.

Key Players covered

The global targeted protein degradation market is consolidated with a few players capturing a major market player.

The report includes the profiles of the following key players:

Arvinas (U.S.)
Bristol-Myers Squibb Company (U.S.)
C4 Therapeutics, Inc. (U.S.)
Degron Therapeutics (China)
Nurix Therapeutics, Inc. (U.S.)
Kymera Therapeutics, Inc. (U.S.)

Key Industry Developments

February 2024: Arvinas, Inc. received Fast Track designation from the U.S. FDA for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer.
May 2022: Kymera Therapeutics, Inc. presented new preclinical results reinforcing the advantage of irak4 degraders over kinase inhibitors as well as first stat3 degrader results in a preclinical model of th17 inflammation.